Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald L Lamm

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
The Journal of Urology|October 24, 2012
A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancerJames M Burke, Donald L Lamm, Maxwell V Meng, et al.
Urologic Oncology|March 26, 2017
A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancerNicholas M Donin, Karim Chamie, Andrew T Lenis, et al.
Urologic Oncology|July 31, 2017
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim resultsVignesh T Packiam, Donald L Lamm, Daniel A Barocas, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not MatterAshish M Kamat, Niyati Lobo, Seth P Lerner, et al.
Urologic Oncology|June 7, 2021
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCGRyan L Steinberg, Vignesh T Packiam, Lewis J Thomas, et al.
Journal for Immunotherapy of Cancer|August 16, 2017
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinomaAshish M Kamat, Joaquim Bellmunt, Matthew D Galsky, et al.
The Journal of Urology|December 11, 2019
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder CancerRyan L Steinberg, Lewis J Thomas, Nathan Brooks, et al.
Nature Medicine|June 6, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
European Urology|August 25, 2024
Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient SelectionRoger Li, Patrick J Hensley, Shilpa Gupta, et al.
European Urology|January 30, 2023
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER StudyNoah M Hahn, Michael A O'Donnell, Jason A Efstathiou, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The Journal of Urology|October 24, 2012
A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancerJames M Burke, Donald L Lamm, Maxwell V Meng, et al.
Urologic Oncology|March 26, 2017
A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancerNicholas M Donin, Karim Chamie, Andrew T Lenis, et al.
Urologic Oncology|July 31, 2017
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim resultsVignesh T Packiam, Donald L Lamm, Daniel A Barocas, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not MatterAshish M Kamat, Niyati Lobo, Seth P Lerner, et al.
Urologic Oncology|June 7, 2021
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCGRyan L Steinberg, Vignesh T Packiam, Lewis J Thomas, et al.
Journal for Immunotherapy of Cancer|August 16, 2017
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinomaAshish M Kamat, Joaquim Bellmunt, Matthew D Galsky, et al.
The Journal of Urology|December 11, 2019
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder CancerRyan L Steinberg, Lewis J Thomas, Nathan Brooks, et al.
Nature Medicine|June 6, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
European Urology|August 25, 2024
Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient SelectionRoger Li, Patrick J Hensley, Shilpa Gupta, et al.
European Urology|January 30, 2023
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER StudyNoah M Hahn, Michael A O'Donnell, Jason A Efstathiou, et al.
Pageof 3